亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial

左炔诺孕酮 医学 产科 宫内节育器 人口 计划生育 妇科 研究方法 环境卫生
作者
Jeffrey T. Jensen,Eeva Lukkari‐Lax,Andrea Schulze,Yesmean Wahdan,Marco Serrani,Robin Kroll
出处
期刊:American Journal of Obstetrics and Gynecology [Elsevier BV]
卷期号:227 (6): 873.e1-873.e12 被引量:22
标识
DOI:10.1016/j.ajog.2022.09.007
摘要

Background

The 52-mg levonorgestrel-releasing intrauterine system is an established, long-acting contraceptive option with approved use for up to 7 years.

Objective

The Mirena Extension Trial evaluated the efficacy and safety of the 52-mg levonorgestrel-releasing intrauterine system during extended use beyond 5 and up to 8 years.

Study Design

This was a multicenter, single-arm study in the United States, enrolling existing users of the 52-mg levonorgestrel-releasing intrauterine system, aged 18 to 35 years, who have had the system for 4.5 to 5 years. We assessed the contraceptive efficacy (Pearl Index) and cumulative failure rate (using the Kaplan–Meier method) of the 52-mg levonorgestrel-releasing intrauterine system during extended use. We also evaluated bleeding outcomes and adverse events.

Results

Of the 362 participants starting year 6, 243 entered and 223 completed 8 years of 52-mg levonorgestrel-releasing intrauterine system use. Just more than half the participants were parous. The mean (standard deviation) age was 29.2 (±2.9) years, and all participants were aged ≤36 years at the end of year 8. Two pregnancies occurred, both with the device in situ. The year 6 pregnancy was of undetermined location and resolved spontaneously. The pregnancy in year 7 was ectopic and resolved with methotrexate treatment. In both cases, the 52-mg levonorgestrel-releasing intrauterine system was removed and the participants left the trial. For years 6 to 8, the 3-year Pearl Index (95% confidence interval) was 0.28 (0.03–1.00) with a 3-year cumulative failure rate of 0.68% (0.17–2.71). Pearl Indexes for years 6, 7, and 8 were 0.34 (0.01–1.88), 0.40 (0.01–2.25), and 0.00 (0.00–1.90), respectively. The 3-year (years 6–8) ectopic pregnancy Pearl Index was 0.14 (0.00–0.77). We found treatment-emergent adverse events in 249 of 362 participants (68.8%), with 65 (18.0%) events considered to be related to the 52-mg levonorgestrel-releasing intrauterine system. The discontinuation rate was 38.4% (139/362), most commonly because of desire for pregnancy (12.2%, 44/362). During extended use beyond 5 years and up to 8 years, participants reported a decrease in the mean number of bleeding or spotting days with approximately half of the women experiencing amenorrhea or infrequent bleeding. We did not enroll a sufficient number of women using the 52-mg levonorgestrel-releasing intrauterine system for contraception and heavy menstrual bleeding to assess extended use for that indication. At the end of year 8, most (98.7%, 220/223) of the participants who completed the study remained satisfied with the continued use of the 52-mg levonorgestrel-releasing intrauterine system. Of the 31 women who discontinued early because of desire for pregnancy with evaluable data for return-to-fertility analysis, 24 reported a posttreatment pregnancy within 1 year, giving a 12-month return-to-fertility rate of 77.4%.

Conclusion

The 52-mg levonorgestrel-releasing intrauterine system, initially approved for 5 years, maintains high contraceptive efficacy, user satisfaction, and a favorable safety profile through 8 years of use. Participants reported 26 posttreatment pregnancies in total, of which 24 occurred in women who had discontinued the 52-mg levonorgestrel-releasing intrauterine system because of a desire for pregnancy. Of note, among women who elected to continue use through 8 years, bleeding patterns remained highly favorable. These findings support continued 52-mg levonorgestrel-releasing intrauterine system use for up to 8 years in women who wish to continue treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
15秒前
duan完成签到 ,获得积分10
17秒前
holder完成签到,获得积分10
37秒前
39秒前
沐白发布了新的文献求助10
43秒前
45秒前
刘宇童发布了新的文献求助10
50秒前
大模型应助吕易巧采纳,获得10
1分钟前
迷人问兰完成签到,获得积分10
1分钟前
闪闪映易完成签到 ,获得积分10
1分钟前
1分钟前
吕易巧发布了新的文献求助10
1分钟前
吕易巧完成签到,获得积分10
1分钟前
1分钟前
Liiiiiiiiii发布了新的文献求助10
1分钟前
XuchaoD完成签到,获得积分10
1分钟前
1分钟前
今后应助Liiiiiiiiii采纳,获得10
1分钟前
顾矜应助科研通管家采纳,获得10
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
1分钟前
2分钟前
2分钟前
2分钟前
小张完成签到 ,获得积分10
2分钟前
可耐的冰萍完成签到,获得积分10
2分钟前
充电宝应助干净涵梅采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
李李发布了新的文献求助10
3分钟前
科研通AI5应助李李采纳,获得10
3分钟前
爱笑的毛衣完成签到,获得积分10
3分钟前
太叔丹翠完成签到 ,获得积分10
3分钟前
沉默白猫完成签到 ,获得积分10
3分钟前
3分钟前
sowhat完成签到 ,获得积分10
3分钟前
孙老师完成签到 ,获得积分10
3分钟前
盛事不朽完成签到 ,获得积分10
3分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270976
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228